Simpson Thacher has advised Japanese pharmaceutical company Sumitomo Pharma on its JPY113 billion (USD711 million) global offering of 51,304,400 newly issued shares.
The team included Tokyo-based partner Takahiro Saito and associates Weiwei Chen and Yoshimi Koshiishi; Washington DC-based partner Vanessa Burrows and associate Alison Peters; New York-based counsel Michael Mann and associate Jacob Madden; and Boston-based senior counsel George Gerstein.
SMBC Bank International, Daiwa Capital Markets Europe, Nomura International and Mizuho International acted as international lead managers.
The global equity offering includes an overallotment option and comprises an international offering to institutional investors outside Japan pursuant to rule 144A of the US Securities Act of 1933, as well as to institutional investors outside Japan and the US pursuant to regulation S under the same act.
Sumitomo Pharma is involved in the discovery, development, manufacturing and commercialisation of prescription pharmaceuticals, including drugs and biologics such as regenerative medicine and cell therapy programmes.
